EUCTR2018-000377-68-HU进行中（未招募）1 期
A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 218
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1-Age = 18 years
- •2-Written informed consent
- •3-Histologically or cytologically confirmed adenocarcinoma of the pancreas
- •4-Metastatic or locally advanced disease that is considered unresectable 5-Measurable / assessable disease according to RECIST v.1.1
- •6-Documented disease progression on first line FOLFIRINOX
- •7-Negative pregnancy test
- •8-Both male and female patients and their partners of childbearing potential must agree to use two medically accepted methods of contraception (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], or one of the following methods of birth control (intrauterine devices, tubal sterilization or vasectomy) or must practice complete abstinence from intercourse of reproductive potential during the course of the study and for 90 days after last treatment
- •(excluding women who are not of childbearing potential and men who have been sterilized).
- •9-ECOG performance status 0 or 1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 153
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 65
排除标准
- •1-Cardiovascular disease, New York Heart Association (NYHA) III or IV 2-History of severe supraventricular or ventricular arrhythmia
- •3-History of coagulation or bleeding disorder
- •4-History of acute myocardial infarction within 6 months before randomization
- •5-History of congestive heart failure
- •6-Acute or chronic inflammation (autoimmune or infectious)
- •7-Significant active/unstable non-malignant disease likely to interfere with study assessments
- •8-Laboratory tests (hematology, chemistry) outside specified limits:
- •a-WBC = 3 x 10³/mm³
- •b-ANC = 1.5 x 10³/mm³
- •c-Platelets = 100,000/mm³
- •d-Hb = 9.0 g/dl (= 5.6 mmol/l)
- •e-aPTT > 1.5 x ULN
- •f-Serum creatinine > 2.0 mg/dl (> 176.8 µmol/l)
- •g-AST and/or ALT > 2.5 x ULN; for patients with significant liver metastasis AST and/or ALT > 5 x ULN
- •h-Alkaline phosphatase > 2.5 x ULN
- •i-Total bilirubin > 2 x ULN
- •j-Albumin < 2.5 g/dL
- •9-Clinically significant ascites
- •10-Any anti-tumor treatment (except FOLFIRINOX as the first-line therapy) for pancreatic adenocarcinoma before enrollment. Note: Patients who have undergone surgical interventions for pancreatic adenocarcinoma will be eligible.
- •11-Any radiotherapy for pancreatic adenocarcinoma before enrollment except for treatment of bone metastases if target lesions are not included in the irradiated field
- •12-Major surgery < 4 weeks prior to enrollment
- •13-Pregnant or nursing
- •14-Investigational medicinal product < 4 weeks of enrollment
- •15-Documented HIV history
- •16-Active hepatitis B infection requiring acute therapy
- •Note: Subjects infected by the hepatitis B virus will be eligible for the study if they have no signs of hepatic decompensation and meet the liver function tests eligibility criteria.
- •17-Known hypersensitivity to any component of the EndoTAG-1 and/or gemcitabine formulations
- •18-History of malignancy other than pancreatic cancer < 3 years prior to enrollment, except non-melanoma skin cancer or carcinoma in situ of the cervix treated locally
- •19-Vulnerable populations (e.g. subjects unable to understand and give voluntary informed consent)
研究者
相似试验
进行中（未招募）
1 期
Treatment for Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreasnresectable Locally Advanced/ Metastatic Adenocarcinoma of the PancreasMedDRA version: 20.0Level: PTClassification code 10001141Term: AdenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000377-68-FRSynCore Biotechnology Co., Ltd.218
已完成
1 期
Phase I Clinical Trial of SII Yellow Fever VaccineCTRI/2020/09/027594Serum Institute of India Pvt Ltd60
进行中（未招募）
1 期
An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301+SOC vs SOC in hospitalized participants with COVID-19 requiring supplemental oxygeCoronavirus disease 2019 (COVID-19)MedDRA version: 20.0Level: LLTClassification code 10061986Term: SARSSystem Organ Class: 100000004862EUCTR2020-002120-37-GBThirty Respiratory Limited300
暂停
1 期
To evaluate the safety, tolerability and efficacy of ZRC COVIMABS in the treatment of mild COVID-19 disease.CTRI/2021/08/036045Cadila Healthcare Ltd
招募中
1 期
Setrusumab vs Bisphosphonates in Pediatric Subjects with Osteogenesis ImperfectaMedDRA version: 20.0Level: PTClassification code: 10031243Term: Osteogenesis imperfecta Class: 100000004850osteogenesis imperfectaCTIS2023-504196-24-00ltragenyx Pharmaceutical Inc.68